TOP - August 2017, Vol 10, No 3
Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies. Read More ›
Each year, >200,000 individuals in the United States are diagnosed with a primary or metastatic brain tumor. Primary brain tumors comprise approximately 40,000 of these diagnoses. Read More ›
Here's what you can expect to find in the August issue of The Oncology Pharmacist. Read More ›
By Chase Doyle
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer. Read More ›
By Chase Doyle
Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects. Read More ›
By Chase Doyle
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon. Read More ›
By Phoebe Starr
Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, Read More ›
By Chase Doyle
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality. Read More ›
By Chase Doyle
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population. Read More ›
By Chase Doyle
Precision medicine continues to transform oncology, and it is not just the treatments that are changing. Read More ›